Meeting
2021 ASCO Annual Meeting
Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial.
Authors
Damien Vasseur
Gustave Roussy, Villejuif, France
Damien Vasseur , Cécile Jovelet , Nathalie Cozic , Julien Mazieres , Fabrice Barlesi , Jaafar Bennouna , Radj Gervais , Lionel Moreau , Henri Berard , Olivier Molinier , Denis Moro-Sibilot , Pierre Jean Souquet , Elodie Amour , Franck Morin , Gerard Zalcman , Jean-Charles Soria , Virginie Westeel , Ludovic Lacroix , Benjamin Besse
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT00775307
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8526)
DOI
10.1200/JCO.2021.39.15_suppl.8526
Abstract #
8526
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Molecular profiling of early-stage colorectal cancer (CRC) using targeted next generation sequencing (NGS) to predict signatures of recurrence.
First Author: Michael C. Burns
Poster
2020 Gastrointestinal Cancers Symposium
Clinical utility of targeted next generation sequencing (NGS) to predict response to neoadjuvant therapy (NT) in rectal cancer (RC).
First Author: Kristen Carroll
Poster
2016 ASCO Annual Meeting
Genetic heterogeneity of KRAS-mutated NSCLC: Co-occurrence of potentially targetable aberrations and evolutionary background.
First Author: Matthias Scheffler
Poster
2022 ASCO Annual Meeting
Dynamic monitoring circulating tumor DNA in plasma samples by PEAC technology for patients with early-stage non–small cell lung cancer after surgery.
First Author: Ning Li